What do you think is the best way to choose an experienced and quality surgeon? Some researchers think it's by reputation. That's how I got mine. A friend told me who he'd use if his wife or mother developed breast cancer and then more and more people began recommending the same surgeon. It seemed logical I'd use him too. And I'm glad I did.

A study published in the January 20 Journal of Clinical Oncology reveals that women who actively choose their surgeons by reputation are more likely to be treated by experienced surgeons in hospitals with comprehensive cancer programs. Reputation even beat out accepting referrals from other doctors or health plans.

Researchers are reporting that a new vaccine designed to treat breast cancer appears to be safe in women with advanced disease. It showed signs of slowing down tumor growth too.

The Neuvenge vaccine, made by Dendreon Corporation -- maker of the Provenge prostate cancer vaccine -- targets the aggressive Her-2 positive form of breast cancer, which affects 20 to 30 percent of breast cancer patients. Using immune cells from a cancer patient's own body, Neuvenge is a tailor-made therapy.

Reports about Neuvenge, published in the Journal of Clinical Oncology, indicate the vaccine did not cause any serious side effects and of the 18 women who participated in the Phase I study, there was a reduction in the size of a tumor in one patient. In three other women, the disease seemed to stabilize for as long as a year.

If you have been through cancer treatment recently, were you given varying opinions from several medical practitioners? If so, you are not alone, as many cancer patients seem to be lost in haze of confusing medical jargon and differing opinions from several doctors.

With more than 1.4 million new cases of cancer due in 2007, one would expect the knowledge and options to be somewhat standard. As we all know, every case if different and there are so many variables at play that a customized treatment set is needed. Do all doctors pay this much attention to each cancer patient? Very doubtful -- there just are not enough specific cancer specialists to go around in my opinion.

The best defense is a good offense, so eating right and taking care of your body in exemplary fashion is a great idea regardless. But, if you end up developing cancer, it may take a decent dose of leaning and aggressiveness to battle through to the other side.

As I worked my way to the check-out cubicle at my oncology office yesterday, I carried with me the small stack of paperwork my doctor had handed me. There was a sheet denoting all my charges -- of course. There were orders for a mammogram and MRI. There was a summary of sorts about my visit. I handed each of these papers to the woman eagerly awaiting receipt of my money -- but before I let them leave my hands, I noticed a check mark on one of the papers. It was located right next to words: No cancer present, in remission. There were other words -- like cancer recurrence -- where my check mark could have landed. But it didn't. I ended up just where I want it be, just where I want it to stay.

A simple check mark brightened my day. It's not that I thought my cancer had returned. It's just that my every-three-month check-ups open the door for this possibility. I go to these appointments for a reason -- to identify cancer's current role in my life -- and so there's always a chance something will be discovered. But not today.

No cancer present, in remission. These are five of the most beautiful words ever written about me.

Join Living Beyond Breast Cancer (LBBC) for a free educational teleconference titled Medical and Quality-of-Life Updates from the 43rd Annual Meeting of the American Society of Clinical Oncology.

The teleconference will be held on Monday, June 11, 2007 at 12:00 p.m. - 1:30 p.m. (EDT). You can participate by using any telephone or by computer using Real Network Player or Windows Media Player. Register online at www.lbbc.com or call 610-645-4567.

This teleconference brings to you groundbreaking research presented at the largest annual conference of cancer professionals in the United States. Some topics discussed will be:

• Advances in surgical, hormonal and chemotherapy treatments
• Using diet and nutrition to improve quality of life
• Clinical trials measuring the long-term impact of treatment on health and well-being
• New information on how to treat and manage metastatic breast cancer

Following the speaker presentation there will be an interactive question and answer session.

The Food and Drug Administration (FDA) will take an additional three months to review Wyeth's kidney cancer drug Torisel -- the first of five new medications the company plans to introduce this year.

The FDA needs more time to investigate data on tumor growth in patients taking Torisel. If all goes well, the drug will be one of only three to effectively hold off incurable kidney cancer. The other two drugs are Pfizer's Sutent and Bayer AG's Nexavar.

Robert Ruffolo, president of Wyeth Research, says he is encouraged by the review process so far. And he is optimistic about launching the product in late 2007.

Studies show Torisel, which will cost patients about $30,000 per year, prolonged survival by 50 percent in those faring poorly with kidney cancer. The sickest kidney-cancer patients were essentially kept alive for 10.9 months, compared with 7.3 months with interferon drugs. Torisel also postponed tumor growth for 5.5 months. This is 77 percent longer than with interferon.

Sutent and Nexavar, both on the market since last year, also slow tumor growth. All three kidney-cancer medicines are of the variety that block the growth of cancer cells -- different from standard chemotherapy which kills tumors and harms nearby tissues too.

Wyeth is relatively new to the oncology market. And soon, the company hopes to launch three more cancer drugs. One, called CMC-544, treats non-Hodgkin's lymphoma. Another, SKI-606, is for chronic myelogenous leukemia. And the third, HKI-272, is for breast cancer.

About 51,000 Americans will be diagnosed with kidney cancer this year.

A study appearing in the Journal of Clinical Oncology reveals there may be something out there that can extend the lives of patients with recurrent prostate cancer.

This something is a new class of anti-cancer targeted drugs that scientists at Cedars-Sinai Medical Center in Los Angeles say are quite promising, despite their ineffectiveness in some prostate cancer patients with no previous chemotherapy treatment.

Pertuzumab, a molecular targeted compound that has been used successfully in ovarian cancer patients, has been shown to block the human epidermal growth factor receptor family by binding to and inhibiting the function of HER2 receptors. They essentially block a key pathway that leads to cancer growth. And this blockage can possibly offer a better, longer life for recurrent prostate cancer patients whose diseases no longer respond to traditional chemotherapy.

Pertuzumab, marketed under the brand name Omnitarg by Roche and Genentech, is just one of many targeted cancer therapies that give researchers hope that cancer may one day be a lifetime disease that can be skillfully managed.

My nose was buried in books just after my breast cancer diagnosis. I craved information and thought the pursuit and acquisition of it would somehow help me gain control over a seemingly uncontrollable disease.

For the most part, reading helps me. But sometimes, I read too much -- "Stop reading", my oncologist instructed me one day after I rambled off a bunch of worries I'd gathered from research -- and I've been known to get overwhelmed by statistics and numbers and theories and clinical jargon. When this happens, I usually find refuge in the personal stories of women living with breast cancer. Those who have weathered the cancer storm are often the real experts on cancer and know how to sift through the details, offering just what's important to all who follow.

For more than a decade, two-time breast cancer survivor Pat McRee searched for the perfect guide she could recommend for women she saw at the Flying Colors cancer resource and support center she directs.

"Too long," "Too detailed," "Overwhelming," "Just plain scary," were the responses she heard about the books she had found.

So she decided to think outside the book, to create her own support guide. An unbook is what she calls it. And it's not too long, too detailed, too overwhelming, or too scary.

Support to Go, The Unbook for the Journey through Breast Cancer is instead a compilation of survivor secrets, affirmations, inspiring quotations, poetry, song lyrics, attitude buttons, funny anecdotes, and referrals to expert resources in oncology, radiology, surgery, psychology, and complementary therapies.

McRee considers her book a support group of sorts, a place where survivors can turn their wild rides into unforgettable journeys.

National Cancer Institute director John Neiderhuber worries the NCI 2007 budget could be slashed by five to 10 percent. And he worries that key cancer research will inevitably come to a halt as a result.

Worries stem from budget cuts proposed by President Bush. Cuts would cost the NCI between $36 million and $4.7 billion -- but Bush reports that NCI funding has doubled in the past 10 years and would still remain relatively high. And due to the recent American Cancer Society announcement that cancer deaths dropped for the second straight year, White House spokesman Tony Fratto says, "We're proud of the significant investment that we have made in cancer research. We're also proud of the results showing that researchers are delivering on that investment."

But researchers still worry. They worry cuts will undermine their successes. They feel like the rug is being pulled out from under them, just as they are making significant progress. They suspect 95 clinical trials could be postponed or cancelled, 3,000 patients could miss the opportunity of joining a trial, and some cancers will be completely eliminated from studies.

"There is a real cost in human life," says Allen Lichter, executive vice president of the American Society of Clinical Oncology, of the more-than-monetary toll budget cuts will take on NCI research efforts.

One study already on hold, pending funding decisions, is the next phase of a study evaluating whether a class of drugs called aromatase inhibitors, can prevent breast cancer. Another research group has opted to stop studying brain tumors. This is a huge loss to patients with this type of cancer, says Lichter.

It's a huge loss to all of us really -- because cancer will affect each of us in some way, some day. And so with cut budgets come cut hopes, cut dreams, and sadly -- cut survival.

This year alone, 215,000 women will be diagnosed with breast cancer. And sadly, not all of them will be treated equally.

Researchers reported last Tuesday that breast cancer patients who are either obese or poor are more likely to receive lower doses of chemotherapy. This might be why some women relapse and others do not, according to the researchers whose findings appear in the Journal of Clinical Oncology.

This treatment discrepancy seems to stem from doctors who mean well and want to save certain women from severe side effects of chemotherapy. Doctors may be under-dosing obese patients, for example, because a larger dose based on weight could lead to worse side effects. There is no evidence this is true, however.

As for socioeconomic status, researchers report doctors are assuming less-educated patients won't stick with a tough course of treatment -- and so they prescribe less, in hopes patients will complete the regimen.

Researchers found that severely obese women were four times more likely to get less chemotherapy than they need. Women with less than a high school education were three times more likely to receive low doses of chemotherapy. And women living in the South were almost six times more likely to come up short on the drugs they need to save their lives.

"We have new therapies and cures out there for many forms of cancer and sadly, sometimes we're not curing people because they are not getting the full doses that should be standard," says Dr. Gary Lyman who led the study at the University of Rochester Medical Center in New York.

A clinical study involving 1,000 prostate cancer patients was stopped this week by Southwest Oncology Group in Michigan due to concerns the treatment may have caused leukemia in three of the participants.

The men in the study received the chemotherapy drug mitoxantrone, thought to possibly improve survival rates for those with poor prognoses following prostate surgery. But before results could be measured, leukemia struck and researchers halted the study, declaring the leukemia findings "an unacceptable risk to patients."

While the assumption is that the drug caused the leukemia -- a disease commonly associated with children and the elderly -- it's still unproved at this point.

Mitoxantrone is not a worthless drug, say some experts. Since its release a decade ago, it has been used to decrease bone pain for men with advanced prostate cancer and to treat multiple sclerosis and, ironically, adult leukemia.

At one time, patients with blood cancers were treated with harsh drugs, like interferon or hydroxyurea, yet only two to three percent would ever achieve any sort of remission. Many would suffer such extreme side effects from these drugs they would stop taking the medication early, decreasing even further their potential odds for survival.

The fate of these patients is changing. And the proof is in print -- in today's issue of the New England Journal of Medicine.

It all began with the study of a highly targeted molecular therapy called STI571 -- designed to block the genetic aberration that gives rise to chronic myeloid leukemia (CML), a disease that affects about 6,000 Americans every year. A clinical trial followed, and a compound marketed by the drug company Novartis emerged. Today, this compound is know as Gleevec.

In the clinical trial of Gleevec, 1,106 CML patients were randomly chosen to receive either Gleevec or Interferon. Early results were so encouraging that all but three percent of the participants using Interferon switched to Gleevec. Five-year survival rates were 89 percent. And 93 percent of patients saw no progression to the acute phase of the disease. Many patients witnessed their blood counts return to normal, and a large number experienced a reverse in the gene mutation that causes CML. Virtually no one reported side effects while using the drug.

Despite a rare reaction that can cause heart failure, Gleevec has now been approved by the FDA for the treatment of six other rare, life-threatening disorders. And other drugs similar in nature to Gleevec are hitting the scene. Some believe long-term suppression of CML will come from a cocktail of these types of drugs.

For now, Gleevec -- on its own -- is a success story.

Steve, my rat terrier, has been having a problem with his eye for about two months. After four visits to two different veterinarians I was referred to the Red Bank Veterinary Hospital in North Jersey. What an amazing place. I did not know that a place like this existed. It was a real hospital but for animals. I was taking my dog to an animal hospital nearby but this was an entirely different experience. I wish I would have gotten him to this place sooner. I scheduled an appointment for their ophthalmologist, Michael J. Ringle, DVM. He knew what was wrong with Steve after about 5 minutes of examination. He used special equipment to look at his eyes and had a diagnosis and plan of action right away.

I was sad when I learned what Steve had was a degenerative eye disease and that without surgery he could go blind. I was however thrilled to get a diagnosis so quickly and actually was expecting them to tell me they didn't know what was wrong with Steve since I have been hearing that for two months. Steve will get surgery next Tuesday and I'm confident he will be fine under the care of Dr. Ringle.

What does this have to do with cancer? Well, when I was in the waiting room I met a women who was with her dog who was getting his second chemotherapy treatment. He was diagnosed with lymphoma. I was so impressed with this place that I wanted to share some information about what they offer at the Red Bank Veterinary Hospital.

The Red Bank Veterinary Hospital offers the most state-of-the-art medicine. RBVH has become the country's largest privately owned veterinary hospital with a general medicine and surgery practice, 24 hour emergency and critical care service, and specialty practice, which includes Avian and Exotics, Cardiology, Critical Care, Dentistry and Oral Surgery, Dermatology and Allergy, Internal Medicine, Neurology, Oncology/Radiation Therapy, Ophthalmology, and Surgery.

Cervical cancer is the second leading cause of cancer deaths among women worldwide. The World Health Organization has estimated that each year over 500,000 women will be diagnosed with cervical cancer and over 300,000 women will die of the disease. Cervical cancer is caused by a chronic infection with high-risk subtypes of the human papillomavirus (HPV). Two of these high-risk subtypes cause more than sixty percent of cervical cancers globally.

The impact of the widespread adoption of the HPV vaccination in Mexico showed that it could potentially drop the cases of cervical cancer by 59 percent. They showed that the biggest impact would be to girls given the vaccination at the age of ten.

Dr. Adriana Bermudez, who is a professor of gynecologic oncology and vice president elect of the International Gynecologic Cancer Society, says "This study shows the potential impact of the new prophylactic HPV vaccines in the Americas. We will need a major public-private partnership to make these vaccines available to the girls and women of the Americas, as well as a major educational campaign to alert parents to the importance of protecting their daughters from cervical cancer."

The International Gynecologic Cancer Society is a non-profit professional society with 1200 members from 80 countries dedicated to reducing the global burden of women's cancers through education and research.